Ilya Pharma announced that is has now raised an additional Euros 3 million in a new targeted share issue. The funds will facilitate continued growth and take the company through the first clinical study and […]
OptiBiotix Health plc (AIM: OPTI) announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan (“Bened”). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and […]
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an agreement with a US company (“The Company”) for the use […]
Carbiotix, an award winning biotechnology start-up focused on optimizing gut health with soluble fiber (prebiotics), has closed a second pre-seed financing round of 450,000 Euros, bringing the total capital raised to date to 700,000 Euros. Participating in […]
Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today announced that Alison Lawton, Kaleido’s president and chief operating officer (COO), has been appointed to […]
Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be […]
Beiersdorf AG, Hamburg, Germany, and S-Biomedic NV, Beerse, Belgium, today announced that they have entered into a cooperation to jointly drive the future of skin care via research into skin microbiota. Accordingly, Beiersdorf has taken […]
AgBiome LLC, a private company harnessing the plant microbiome for novel agricultural pest solutions, announced today that it has secured $65 million in Series C financing that will help the company bring novel crop protection […]
Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based […]
Paris (France), July 5, 2018 – Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major inflammatory bowel diseases, today announced that it has completed a €7m Series […]
On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. BioGaia has now, after the set milestones have been achieved, decided to further extend its holding, resulting in a […]